# Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery

> **NCT00404014** · PHASE2 · COMPLETED · sponsor: **Allon Therapeutics** · enrollment: 234 (actual)

## Conditions studied

- Mild Cognitive Impairment

## Interventions

- **DRUG:** AL-208
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00404014
- **Lead sponsor:** Allon Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-06
- **Final completion:** 2008-06
- **Target enrollment:** 234 (ACTUAL)
- **Last updated:** 2012-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00404014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00404014, "Study to Evaluate Safety, Tolerability, and Effect of AL208 on Mild Cognitive Impairment Following Coronary Artery Bypass Graft Surgery". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00404014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*